The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
I wonder if they need a broad spectrum antiviral for that war chest?! Apologies if already posted.
https://www.gov.uk/government/speeches/how-the-world-should-prepare-for-the-next-pandemic
Did anyone spot this in the RNS today:
“ In these experiments, Vero E6 cells were treated with SNG001 prior to and after infection with SARS-CoV-2”
If they are still aiming to sell this as a prophylactic it would significantly future revenue prospects.
Well done to all the long term holders today, the last few weeks have been tough, but we are kind of used it by now and know it will come good in the end.
Not sure the chickens will be pleased though.
https://www.arabnews.com/node/1174926/food-health
Judging by you post history maybe investing is not for you. AIM investors generally have no patience and have jumped ship to the latest shiney share. As soon as news drops they will be back in there droves. Inclusion in ACTIV2 took us from 80p to 1.90. Progress from P2 to P3 in ACTIV2 should do much more than that as it completely de-risks this investment. We should have news on this any time between now and the next 4 weeks. I still have faith that SNG will be able to match And break all of the brokers predictions. Can you imagine if the ACTIV2 progression RNS comes with a pre order from Uncle Sam?
Ladders, yes the home trial covers a 90 day check in which is assessing long COVID. This trial closed back in January so results are due any day now and should land by mid May at the latest. Personally I’m optimistic for Monday, but you can never predict with Synairgen. In terms of when the drug is available, it is currently via MAP. But for wide use we would need an EUA or full authorisation which could result from our 3 ongoing trials.